Ozempic packets at a Novo Nordisk facility.
When the company’s shares become more than 10% of Danish fund managers’ holdings, they are forced to sell.
Photo: Carsten Snejbjerg/Bloomberg NewsThe company behind diabetes and obesity phenomena Ozempic and Wegovy is overweight.
Novo Nordisk became Europe’s most valuable company last month, overtaking luxury goods maker LVMH, which itself took the title from food giant Nestlé in 2021.
This might be a reason why the shares trade at a discount to those of its closest peer, U.S.-listed Eli Lilly .
Persons:
Carsten Snejbjerg, Eli Lilly
Organizations:
Novo Nordisk, Bloomberg
Locations:
Novo, Danish